The evaluation discusses 58 peptides in different clinical phases, indicating a sturdy pipeline of peptide therapies focusing on PPIs. Small protein and peptide therapeutics produced by genetic code enlargement also have a short half-lifetime thanks to their weak pharmacokinetics, which include quick serum degradation and quick elimination. Atta